GeorgeBuddMD

PubMed

• 10 citations
  A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
  Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem
  European Journal of Cancer. 2022-11-01
• 3 citations
  Impact of early detection on cancer curability: A modified Delphi panel study.
  Lee Schwartzberg, Michael S Broder, Sikander Ailawadhi, Himisha Beltran, L Johnetta Blakely
  Plos One. 2022-01-01
• Association between biologically effective dose and local control after stereotactic body radiotherapy for metastatic sarcoma.
  Eashwar Somasundaram, Timothy D Smile, Ahmed Halima, James B Broughman, Chandana A Reddy
  Journal of Radiosurgery and SBRT. 2022-01-01

Journal Articles

• Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: An Integrated Safety Analysis  
  Dieras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, Chernyukhin N, Smitt MC, Krop IE, Journal of Clinical Oncology, 7/14/2014
• Cardioprotective effect of Beta-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure  
  Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH, Circ Heart Fail, 5/1/2013
• Supplement use during an intergroup clinical trial for breast cancer (S0221)  
  Zirpoli GR, Brennan PM, Hong C-C, McCann SE, Ciupak G, Davis W, Unger JM, Budd GT, Hershman DL, Moore HCF, Stewart J, Isaacs C, Hobday T, Salim M, Hortobagyi GN, Gralo..., Breast Cancer Res Treat, 2/1/2013
• Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase II trial S0221for breast cancer  
  Yao S, Sucheston LE, Barlow WE, Zirpoli G, Liu S, Moore HCF, Budd GT, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagyi GN, Gralow ..., The Pharmacogenomics Journal, 1/1/2013
• HER4 Expression Status Correlates with Improved Outcome in Both Neoadjuvant and Adjuvant Trastuzumab Treated Invasive Breast Carcinoma  
  Portier BP, Minca EC, Wang Z, Lanigan CL, Gruver AM, Downs-Kelly ED, Budd GT, Tubbs RR, Oncotarget, 1/1/2013
• Circulating tumor cells in biliary cancer: First step or false step? (editorial)  
  Budd GT, Journal of Gastrointestinal Oncology, 6/1/2012
• Impact of Postmastectomy Radiation on Locoregional Recurrence in Breast Cancer Patients With 1-3 Positive Lymph Nodes Treated With Modern Systemic Therapy  
  Tendulkar RD, Rehman S, Shukla ME, Reddy CA, Moore H, Budd GT, Dietz J, Crowe JP, Macklis R, Int J Radiat Oncol Biol Phys, 5/4/2012
• A common copy-number breakpoint of ERBB2 amplification in breast cancer colocalizes with a complex block of segmental duplications  
  Marotta M, Chen X, Inoshita A, Robert Stephens R, Budd GT, Crowe JP, Lyons J, Kondratova A, Tubbs RR, Tanaka H, Breast Cancer Research, 1/1/2012
• Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)  
  Sucheston LE, Zhao H, Yao S, Zirpoli G, Liu S, Barlow WE, Moore HC, Thomas Budd G, Hershman DL, Davis W, Ciupak GL, Stewart JA, Isaacs C, Hobday TJ, Salim M, Hortobagy..., Breast Cancer Res Treat, 12/1/2011
• A young woman with a breast mass: What every internist should know  
  Wesolowski R, Budd GT, Cleve Clin J Med, 8/1/2010
• Phase II Clinical Trial of Imatinib Mesylate in Therapy of KIT and/or PDGFR(alpha)-expressing Ewing Sarcoma Family of Tumors and Desmoplastic Small Round Cell Tumors  
  Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA, Anticancer Res, 2/1/2010
• Let me do more than count the ways: What circulating tumor cells can tell us about the biology of cancer  
  Budd GT, Molecular Pharmaceutics, 9/1/2009
• Neoadjuvant therapy for breast cancer: assessing treatment progress and managing poor responders  
  Wesolowski R, Budd GT, Current Oncology Reports, 1/1/2009
• Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter Phase II trial  
  Olson JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight Jr GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ, Journal of the American College of Surgeons, 1/1/2009
• Outcome of Early Stage Breast Cancer Patients Treated with Doxorubicin-Based Adjuvant Chemotherapy as a Function of HER2 and TOP2A Status: Southwest Oncology Group Dir...  
  Tubbs RR, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh I-T, Sledge G, Shapiro C, Ingle, Haskell C, Albain KS, Livingston RB, Hayes DF, Journal of Clinical Oncology, 1/1/2009
• Subcutaneous implantable veous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series  
  Almhanna K, Pelley RJ, Budd GT, Davidson J, Moore HCF, Anti-Cancer Drugs, 9/1/2008
• The Expression of the Cytoskeletal Focal Adhesion Protein Paxillin in Breast Cancer Correlates with HER2 Overexpression and May Help Predict Response to Chemotherapy: ...  
  Short S, Yoder B, Tarr S, Prescott N, Laniauskas S, Coleman K, Downs-Kelly E, Pettay J, Choueiri T, Crowe J, Tubbs RR, Budd GT, Hicks DG, The Breast Journal, 1/1/2007
• Incidence of advanced symptomatic disease as primary endpoint in screening and prevention trials  
  Nancy A. Obuchowski NA, Schoenhagen P, Modic MT, Meziane M, Budd GT, American Journal of Roentgenology, 1/1/2007
• Intimal Pulmonary Artery Sarcoma Presenting As Dyspnea: Case Report Department of Internal Medicine, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA; Depar...  
  Hsing JM, Thakker SG, Borden EC, Budd GT, International Seminars in Surgical Oncology, 1/1/2007
• Unusual Macular Degeneration Following Breast Cancer Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH, USA, Department of Oncology, Cleveland Clinic Foun...  
  Margolis R, Budd GT, Singh AD, ACTA Ophthalmologica Scandinavica, 1/1/2007
• HER-2 amplification in tubular carcinoma of the breast  
  Oakley III GJ, Tubbs RR, Crowe J, Sebek B, Budd GT, Patrick RJ, Procop GW, American Journal of Clinical Pathology, 1/1/2006
• Phase I trial of Anvirzel™ in patients with refractory solid tumors  
  Mekhail T, Kaur H, Ganapathi R, Budd GT, Elson P, Bukowski RM, Investigational New Drugs, 1/1/2006
• Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer  
  Ring BZ, Seitz RS, Beck R, Shasteen WJ, Tarr SM, Cheang MCU, Yoder BJ, Budd GT, Nielsen TO, Hicks DG, Estopinal NC, Ross DT, Journal of Clinical Oncology, 1/1/2006
• Circulating tumor cells predict progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients  
  Daniel F. Hayes, Massimo Cristofanilli, G. Thomas Budd, Matthew J. Ellis, MB, PhD, Alison Stopeck, M. Craig Miller, Jeri Matera, W. Jeffrey Allard, Gerald V. Doyle, Le..., Clinical Cancer Research, 1/1/2006
• HER2 status in bilateral breast cancer  
  Crowe JP, Patrick RJ, Rybicki LA, Budd GT, Escobar PF, Tubbs RR, Hicks DG, Int J Womens Med, 1/1/2006
• Join now to see all

Books/Book Chapters

• Cancer in the Spine, Comprehensive Care 
  Chapter: Metastatic Breast Carcinoma. 
  Page 117 - 121Hill J and Budd GTEditors: McLain RF.Humana Press, Totowa, NJ2006
• Atlas of Cancer 
  Chapter: Breast Cancer 
  Page 380 - 449Crowe J and Budd GTEditors: Markman.Lippincott Williams & Wilkins2003
• Colon Cancer Prevention 
  Chapter: Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. 
  Page 45 - 53Stoner GD, Budd GT, Ganapathi R, DeYoung B, Kresty LA, Nitert M, Fryer B, Church JM, Provencher K, Pamukcu R, Piazza G, Hawk E, Kelloff G, Elson P, van Stolk RUEditors: AAICR.Kluwer Academic/Plenum Publishers, New York1999
• The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy 
  Chapter: Comment on Future Directions 
  Budd GTEditors: Rustum Y and McGuire JJ.Plenum Press, New York1998
• Medicine for the Practicing Physician 
  Chapter: Waldenstrom's Macroglobulinemia. 
  Page 879 - 881Budd GTEditors: Hurst JW.Appleton and Lange, Stamford, CT1996
• Biology of renal cell carcinoma 
  Chapter: Cytokine therapy of metastatic renal cell carcinoma: The Cleveland Clinic experience. 
  Page 189 - 203Bukowski RM, Olencki T, Peereboom D, Budd GT, Murthy S, Tubbs R, Rayman P, McLain D, Klein E, Tuason L, Finke JEditors: Bukowski RM, Finke JH, Klein EA.Springer-Verlag, New York1995
• Cancer Treatment: an Update 
  Chapter: Phase II trial of fluorouracil, leucovorin, and interferon-alpha. 
  Page 428 - 432Bukowski RM, Gibson V, Murthy S, McLain D, Olencki T, Budd GEditors: Banzet P, Holland JF, Khayat D, Weil M.Springer-Verlag, Paris1994
• Clinical Preventive Medicine 
  Chapter: Breast Cancer 
  Page 908 - 916Bhattia A and Budd GTEditors: Matzen and Lang.Matzen and Lang, St. Louis1993
• The Mechanism and New Approach on Drug Resistance of Cancer Cells 
  Chapter: Modulation of clinical doxorubicin resistance: application of laboratory concepts and future directions. 
  Page 267 - 278Ganapathi R, Budd T, Bukowski REditors: Miyazaki T, Takaku F, and Sakurada K.Elsevier Science Publishers, V.B.1993
• Clinical Preventive Medicine 
  Chapter: Breast Cancer. 
  Page 908 - 916Bhattia A and Budd GTEditors: Matzen and Lang.Mosby Year Book, St. Louis1993
• Immunotherapy of Renal Cell Carcinoma, Clinical and Experimental developments 
  Chapter: Phenotypic and functional analysis of lymphoid cells in the peripheral blood and tumor of cancer patients treated with recombinant Interleukin-2 plus Interferon-alpha. 
  Budd GT, Finke JH, Tubbs R, Edinger M, Stanley J, Murthy S, Sergi JS, Medendorp SV, Gibson V, Bauer L, Bukowski REditors: Bukowski and Klein.Marcel Dekker, New York1993
• Combination Therapies: Biologic Response Modifiers in the Treatment of Cancer and Infectious diseases 
  Chapter: IL-2 Based combination therapy of malignant disease: summary of the Phase I experience at the Cleveland Clinic. 
  Page 49 - 56Budd GT, Murthy SV, Finke J, Tubbs RR, Alexander J, Gautam S, Sergi J, Bukowski REditors: Goldstein AL and Garaci E.Plenum Publishing, New York1992
• Immunotherapy of Renal Cell Carcinoma, Clinical and Experimental developments 
  Chapter: Combination therapy of renal cell carcinoma with Interleukin-2 and Interferon Alpha: The Cleveland Clinic Experience. 
  Page 113 - 118Budd GT, Sergi J, Finke J, Barna B, Boyett J, Medendorp S, Murthy S, Tubbs R, Gibson V, Pontes JE, Bukowski RMEditors: Debruyne FMJ, Bukowski RM, Pontes JE, de Mulder PHM.Springer-Verlag, Berlin, Heidelberg1991
• Biologic Agents in the Treatment of Cancers 
  Chapter: Interleukin-2 and Interferon Alpha2a: The Cleveland Clinic Experience in renal cell carcinoma. 
  Page 339 - 401Budd GT, Sergi J, Finke J, Tubbs R, Boyett J, Murthy S, Gibson V, Bukowski RMEditors: Hersey P.1990
• The Expanding Role of Folates and Fluoropyrimidines in Cancer Chemotherapy 
  Chapter: Comment on Future Directions. 
  Budd GTEditors: Rustum Y and McGuire JJ.Plenum Press, New York1988
• Principles of Cancer Chemotherapy 
  Chapter: Non-clonogenic predictive assays. 
  Page 438 - 445Budd GT, Livingston RBEditors: Carter SK, Hellman K.McGraw-Hill, New York1987
• Current Clinical Practice 
  Chapter: Soft tissue and bone sarcomas. 
  Page 361 - 363Budd GTEditors: Messerli FH.W.B. Saunders, Philadelphia1987
• Principles of Cancer Chemotherapy 
  Chapter: Non-clonogenic predictive assays 
  Page 438 - 445Budd GT, Livingston RBEditors: Carter SK, Hellman K.McGraw-Hill, New York1987
• Human Tumor Cloning 
  Chapter: In-vitro phase II trial of 5-FU and folinic acid in non-gastrointestinal malignancy. 
  Budd GT, Neelon REditors: Trent J and Salmon S.Grune and Stratton1984
• Join now to see all

Abstracts/Posters

• "HER2 Positive Breast Cancer Treatments"
  George Thomas Budd, MD, 3rd Multi-disciplinary Approach to Cancer Therapy Conference, Dubai UAE, 1/28/2013
• "SWOG S0221: Comparison of Two Schedules of Paclitaxel as Adjuvant Therapy for Breast Cancer."
  George Thomas Budd, MD, American Society of Clinical Oncology, 1/1/2013
• Automated Quantitative RNA In Situ Hybridization for Resolution of Equivocal and Heterogeneous ERBB2 (HER2) Status in Invasive Breast Carcinoma.
  Wang Z, Portier BP, Gruver AM, Bui S, Wang H, Su N, Vo H-T, Ma X-J, Luo Y, Budd GT, Tubbs RR, Cancer Res, 12/15/2012
• Effect of aspirin (aSp) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27.
  Higgins MJ, Chapman J-AW, Ingle JN, Sledge G, Budd GT, Ellis MJ, Pritchard KI, Clemons M, Badovinac Crnjevic T, Han L, Gelmon K, Rabaglio M, Elliott C, Shepherd LE, Go..., Cancer Res, 12/15/2012
• Trastuzumab emtansine in her2-positive metastatic breast cancer: pooled safety analysis from seven studies.
  Dieras V, Harbeck N, Budd GT, Greenson JK, Guardino E, Samant M, Chernyukhin N, Smitt M, Krop IE, Cancer Res, 12/15/2012
• Molecular morphology based genomic Signatures of moderate Complexity predict pathologic Complete response in HER2 molecular breast Carcinoma Class patients treated wit...
  Tubbs RR, Portier BP, Morrison L, Wang Z, Minca E, Lanigan C, Budd GT, Cancer Res, 12/15/2012
• Use of HER2 score correction for putative chromosome 17 (Chr-17) aneusomy to increase eligibility for anti-HER2 therapy.
  Minca, E. C., Portier, B. P., Wang, Z., Lanigan, C., Budd, G. T., & Tubbs, R. R., J Clin Oncol, 5/1/2012
• Use of HER2 score correction for putative chromosome 17 (Chr-17) aneusomy to increase eligibility for anti-HER2 therapy.
  Minca, E. C., Portier, B. P., Wang, Z., Lanigan, C., Budd, G. T., & Tubbs, R. R., ASCO, 5/1/2012
• "Hormone Therapy and Anti-HER2 Therapy."
  George Thomas Budd, MD, 2nd Multi-Disciplinary Approach to Cancer Therapy Conference, Dubai International Convention and Exhibition Centre, Dubai, UAE, 1/25/2012
• "Systemic Therapy of Soft Tissue Sarcomas: If, When, and What."
  George Thomas Budd, MD, 2nd Multi-Disciplinary Approach to Cancer Therapy Conference, Dubai International Convention and Exhibition Centre, Dubai, UAE, 1/25/2012
• Docetaxel, carboplatin, trastuzumab, and bevacizumab (TCHB) for early stage HER2/neu() breast cancer and bone marrow micrometastases.
  J. Baar, P. Silverman, G. T. Budd, L. Gibson, H. Meyerson, P. Fu, D. Diorio, ASCO, 1/1/2012
• Randomized multicenter double-blind phase II trial: The immunological adjuvant OPT-821 with or without a trivalent ganglioside vaccine in metastatic sarcoma patients f...
  R. D. Carvajal, R. Chugh, M. M. Milhem, C. W. Ryan, S. George, B. Chmielowski, M. Agulnik, E. T. Rodler, A. D. Elias, G. T. Budd, H. Tawbi, S. Movva, B. A. Van Tine, M..., ASCO, 1/1/2012
• Adherence to ASCO/CAP HER2 Testing Guidelines: Equivocal Rates and Impact on Management within a Single Institution.
  Portier BP, Downs-Kelly E, Lanigan C, Cotta C, Patil D, Procop G, Cook JC, Moore H, Budd GT, Tubbs RR, Lab Invest, US-Canadian Academy of Pathology Meeting, San Antonio, 2/26/2011
• Cold Ischemia Time: Effect on HER2 Detection by In-Situ Hybridization and Immunohistochemistry.
  Portier BP, Downs-Kelly E, Rowe JJ, Pati D, Budd GT, Lanigan C, Wang Z, Hicks D, Rimm DL, Tubbs RR, Lab Invest, US-Canadian Academy of Pathology Meeting, San Antonio, 2/26/2011
• First analysis of SWOG S0221: A phase III trial comparing chemotherapy schedules in high-risk early breast cancer.
  G. T. Budd, W. E. Barlow, H. C. F. Moore, T. J. Hobday, J. A. Stewart, C. Isaacs, M. Salim, J. K. Cho, K. Rinn, K. S. Albain, H. K. Chew, G. V. Burton, T. D. Moore, G...., J Clin Oncol, 1/1/2011
• Adherence to ASCO/CAP HER2 Testing Guidelines: Equivocal Rates and Impact on Management within a Single Institution.
  Portier BP, Downs-Kelly E, Lanigan C, Cotta C, Patil D, Procop G, Cook JC, Moore H, Budd GT, Tubbs RR, Lab Invest; US-Canadian Academy of Pathology Meeting, San Antonio, February 26-March 4, 2011, 1/1/2011
• Cold Ischemia Time: Effect on HER2 Detection by In-Situ Hybridization and Immunohistochemistry.
  Portier BP, Downs-Kelly E, Rowe JJ, Pati D, Budd GT, Lanigan C, Wang Z, Hicks D, Rimm DL, Tubbs RR, Lab Invest; US-Canadian Academy of Pathology Meeting, San Antonio, February 26-March 4, 2011, 1/1/2011
• Effect of kinesins on taxane resistance.
  R. Wesolowski, M. Orloff, E. Downs-Kelly, G. T. Budd, G. R. Stark, S. De, R. R. Tubbs, J. P. Crowe, C. Eng, J Clin Oncol, 1/1/2010
• Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast C...
  Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI, Proceedings of the 33rd Annual San Antonio Breast Cancer Symposium, 1/1/2010
• Correlation of BCL-2 and Apoptosis on Circulating Tumor Cells and Breast Cancer Tissue.
  Maranci V, Thomas DG, Brown M, Budd GT, Doyle G, Hayes DF, Griffith KA, Smerage J, Proceedings of the 33rd Annual San Antonio Breast Cancer Symposium, 1/1/2010
• "Treating the HER2-Positive Breast Cancer Patient: Challenges and Controversies."
  George Thomas Budd, MD, Karmanos Cancer Institute/Wayne State University School of Medicine, 9/28/2009
• "Genomics in Breast Cancer."
  George Thomas Budd, MD, Challenging Cases in Breast & Lung Cancer., Las Vegas, NV, 9/12/2009
• "Adjuvant Hormonal Therapy"
  George Thomas Budd, MD, Breast Cancer 2009-Advances in Science, Emerging Data and Novel Therapeutics (Breast Cancer Highlights: Highlights from the 31st Annual San Antonio Breast Cancer Symposium), Chicago, IL, 2/7/2009
• "Adjuvant Hormonal Therapy,"
  George Thomas Budd, MD, Breast Cancer 2009-Advances in Science, Emerging Data and Novel Therapeutics (Breast Cancer Highlights: Highlights from the 31st Annual San Antonio Breast Cancer Symposium), San Francisco, CA, 1/24/2009
• "Evolving Insights Into Molecular Subtypes"
  George Thomas Budd, MD, Current Trends in Breast Cancer Meeting, New York, NY, 1/17/2009
• Join now to see all

Lectures

• "Dialogues in practice: Life After Breast Cancer Treatment" (Panel Discussant and Moderator) 
  Berlin, Germany - 10/15/2009
• "Dialogues in practice: Life After Breast Cancer Treatment" 
  Berlin, Germany - 10/15/2009
• "The Most Appropriate Management Strategy for Advanced Breast Cancer Is Single-Agent Therapy: Pro vs Con." 
  Hilton Head, SC - 10/2/2009
• "Treating the HER2-Positive Breast Cancer Patient: Challenges and Controversies." 
  Karmanos Cancer Institute/Wayne State University School of Medicine - 9/28/2009
• "Genomics in Breast Cancer." 
  Las Vegas, NV - 9/12/2009
• "The role of CTC monitoring in breast cancer." 
  New Orleans, LA - 4/19/2009
• "Update: Advanced Breast Cancer." 
  Ft. Lauderdale, FL - 3/5/2009
• "Update: Triple Negative Disease-Progress?" 
  Ft. Lauderdale, FL - 3/5/2009
• "Advances: New Agents for HER2 Positive Breast Cancer." 
  Ft. Lauderdale, FL - 3/5/2009
• "Adjuvant Hormonal Therapy" 
  San Francisco, CA - 1/24/2009
• "Evolving Insights Into Molecular Subtypes" 
  New York, NY - 1/17/2009
• Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial. 
  1/1/2009
• Variants in the BRCA1/Fanconi-Anemia Repair Pathway and Taxane-Induced Neuropathy in SWOG S0221. 
  1/1/2009
• Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer. 
  1/1/2008
•  
  1/1/2008
• HER2 amplification predicts breast cancer recurrence but not overall survival. 
  1/1/2008
• "Validation of genomic markers that predict distant recurrence risk via FISH assays in women with early stage breast carcinoma." 
  1/1/2007
• Discussant:"Minimal Detectable Disease in Breast Cancer Patients: Bone Marrow, Lymph Nodes, and Blood." 
  1/1/2007
• Discussant: "Minimal Detectable Disease in Breast Cancer Patients: Bone Marrow, Lymph Nodes, and Blood." 
  1/1/2007
• "Long-term followup of SWOG 8313: CMFVP vs FAC-M as adjuvant therapy of node-positive, ER-negative breast cancer." 
  12/3/2003
• "The Treatment of Advanced Hormone-Refractory Breast Cancer." 
  Providence Medical Center, Southfield, MI - 11/20/2003
• "Advances in the Treatment of Metastatic Breast Cancer." 
  Rush North Shore Medical Center, Skokie, IL - 11/18/2003
• "Tax 311: Implications for Breast Cancer Therapy." 
  Chicago, IL - 10/1/2003
• "A Phase I Dose-Escalation Trial of ZD6126 Administered as 5 Daily Doses Every 3 Weeks to Patients with Cancer Refractory to Other Treatments." 
  Copenhagen, Denmark - 9/24/2003
• "Locally Advanced Disease: Neo-Adjuvant Therapy." 
  9/18/2003
• Join now to see all

Other

• "Locally Advanced Disease: Neo-Adjuvant Therapy." 
  George Thomas Budd, MD, NOCR Webcast
  9/18/2003